Clinical Trial Update: Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel [Phase 1]

View source ↗

Summary

A Phase 1 crossover trial evaluated bioequivalence between two oral levonorgestrel formulations to support their interchangeability for contraception use.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Contraception
• Postcoital Contraception

Drugs mentioned

• Levonorgestrel (oral formulation A) (levonorgestrel)
• Levonorgestrel (oral formulation B) (levonorgestrel)

Snippet

Sponsor: Bayer | Conditions: Contraception, Contraception, Postcoital | Phase 1 | Status: COMPLETED